The short answer
Older short trials suggest modest urinary-symptom effects; contemporary evidence is limited.
- Evidence and scope
- Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
- Important limitation
- Trials are inconsistent or small, so a reliable clinically important benefit is not established.
- Before deciding
- Key concern: Do not delay prostate evaluation; anticoagulants, hormone therapies, pregnancy, and surgery require review.
01 / PRACTICAL GUIDE
Dose, absorption, and combinations
These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.
Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.
Dose source ↗More is not automatically better. A clinician or product label may specify a different amount.
Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.
Take with meals.
Do not delay prostate evaluation; anticoagulants, hormone therapies, pregnancy, and surgery require review.
Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.
02 / EVIDENCE
What the research says
We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.
These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.
Open the research timelineResearch timeline+
Entries are ordered by publication year. A study period appears only when the source reports it.
Pygeum africanum for benign prostatic hyperplasia
Symptoms and flow measures improved modestly, but trials were small, short, variably formulated, and rarely used validated measures; none compared Pygeum with standard alpha-blockers or 5-alpha-reductase inhibitors. Long-term effectiveness and complication prevention remain unknown.
Study design and methods
- Design
- Cochrane systematic review and meta-analysis of 18 randomized controlled trials
- Population
- 1,562 men with symptomatic benign prostatic hyperplasia
- Intervention
- Pygeum africanum preparations alone or in combinations versus placebo or other controls
- Outcome
- Urinary symptoms, nocturia, residual urine, peak flow, adverse effects, and withdrawals
Funding or conflict note: The review reported no conflicts of interest.
Unscreened discovery appendix—not evidence4 candidate publicationsSearch run: Aug 21, 2026
Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.
03 / SOURCES
Start with the source material
The live search is for discovery only. Search-result counts change and are not included in the audited totals above.
Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.
- A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy.Coulson S, Rao A, Beck SL et al. · 2013 · Complementary therapies in medicine · PMID 23642948Open on PubMed ↗
- Pygeum africanum for benign prostatic hyperplasia.Wilt T, Ishani A, Mac Donald R et al. · 2002 · The Cochrane database of systematic reviews · PMID 11869585Open on PubMed ↗
- Phytotherapy for benign prostatic hyperplasia.Wilt TJ, Ishani A, Rutks I et al. · 2000 · Public health nutrition · PMID 11276294Open on PubMed ↗
- Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension.Chatelain C, Autet W, Brackman F · 1999 · Urology · PMID 10475357Open on PubMed ↗
04 / EXPERT CONTEXT
Expert context—not evidence
Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.
No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.